Long pentraxin-3 inhibits epithelial-Mesenchymal transition in melanoma cells

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2760-2771

  Ronca, Roberto ^a   Salle, Emanuela Di ^a   Giacomini, Arianna ^a   Leali, Daria ^a   Alessi, Patrizia ^a   Coltrini, Daniela ^a   Ravelli, Cosetta ^a   Matarazzo, Sara ^a   Ribatti, Domenico ^b   Vermi, William ^a,c   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; PENTAPEPTIDE; PENTRAXIN 3; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN INTERACTION; TUMOR CELL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; C-REACTIVE PROTEIN; CHICK EMBRYO; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECOMBINANT PROTEINS; SERUM AMYLOID P-COMPONENT; TUMOR BURDEN;

EID: 84890498808     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0487     Document Type: Article

References (50)

1. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355:51-65
2. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010;46:270-83
3. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90
4. Nakamura M, Tokura Y. Epithelial-mesenchymal transition in the skin. J Dermatol Sci 2011;61:7-13
5. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-kappaB/Snail/RKIP/PTEN circuit. Genes Cancer 2010;1:409-20
6. Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 2012;7:e40378
7. Hsu MY, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE, et al. Ecadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000;156:1515-25
8. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78
9. Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 2001;61:7282-90
10. Itoh N, Ornitz DM. Evolution of the FGF and FGFR gene families. Trends Genet 2004;20:563-9
11. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993;60:1-41
12. Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Res 1988;3: 177-86
13. Jeffers M, LaRochelle WJ, Lichenstein HS. Fibroblast growth factors in cancer: therapeutic possibilities. Expert Opin Ther Targets 2002;6: 469-82
14. Valesky M, Spang AJ, Fisher GW, Farkas DL, Becker D. Noninvasive dynamic fluorescence imaging of human melanomas reveals that targeted inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor growth by apoptosis. Mol Med 2002;8:103-12
15. Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu MY, Dejesus E, et al. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 1999;18:6469-76
16. Metzner T, Bedeir A, Held G, Peter-Vorosmarty B, Ghassemi S, Heinzle C, et al. Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. J Invest Dermatol 2011;131:2087-95
17. Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 2002;160: 1009-19
18. Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007;11:723-38
19. Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004;104:92-9
20. Camozzi M, Rusnati M, Bugatti A, Bottazzi B, Mantovani A, Bastone A, et al. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 2006;281:22605-13
21. Leali D, Alessi P, Coltrini D, Ronca R, Corsini M, Nardo G, et al. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol Cancer Ther 2011;10:1600-10
22. Ronca R, Alessi P, Coltrini D, Salle ED, Giacomini A, Leali D, et al. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer. J Pathol 2013;230:228-38
23. Leali D, Alessi P, Coltrini D, RusnatiM, Zetta L, Presta M. Fibroblast growth factor-2 antagonist and antiangiogenic activity of longpentraxin 3-derived synthetic peptides. Curr Pharm Des 2009;15: 3577-89
24. Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, Ragona L, et al. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3- derived antiangiogenic pentapeptide. J Cell Mol Med 2010;14: 2109-21
25. Li D, Wang H, Xiang JJ, Deng N, Wang PP, Kang YL, et al. Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma in vivo and in vitro. Oncol Rep 2010;24:457-63
26. Tsunoda S, Nakamura T, Sakurai H, Saiki I. Fibroblast growth factor-2- induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci 2007;98:541-8
27. Rivieccio V, Esposito A, Bellofiore P, Palladino P, Sassano M, Colombo M, et al. High-level expression and efficient purification of recombinant human long pentraxin PTX3 in Chinese hamster ovary cells. Protein Expr Purif 2007;51:49-58
28. Ronca R, Benzoni P, Leali D, Urbinati C, Belleri M, Corsini M, et al. Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1. Mol Cancer Ther 2010;9:3244-53
29. Ribatti D, Nico B, Cimpean AM, Raica M, Crivellato E, Ruggieri S, et al. B16-F10 melanoma cells contribute to the new formation of blood vessels in the chick embryo chorioallantoic membrane through vasculogenic mimicry. Clin Exp Med 2013;13:143-7
30. Coltrini D, Di Salle E, Ronca R, Belleri M, Testini C, Presta M. Matrigel plug assay: evaluation of the angiogenic response by reverse transcription- quantitative PCR. Angiogenesis 2013;16:469-77
31. Liang G, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012;33: 531-41
32. Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998;17:5896-904
33. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997;276:955-60
34. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 2002;109: 987-91
35. Aguzzi MS, Faraone D, D'Arcangelo D, De Marchis F, Toietta G, Ribatti D, et al. The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo. Mol Ther 2011;19:266-73
36. Facchiano A, Russo K, Facchiano AM, De Marchis F, Facchiano F, Ribatti D, et al. Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties. J Biol Chem 2003;278: 8751-60
37. Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2013;2:e39
38. Cheng YM, Chou CY, Hsu YC, Chen MJ, Wing LY. The role of human papillomavirus type 16 E6/E7 oncoproteins in cervical epithelialmesenchymal transition and carcinogenesis. Oncol Lett 2012; 3:667-71
39. Sakuma K, Aoki M, Kannagi R. Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 2012;109:7776-81
40. Savagner P, Valles AM, Jouanneau J, Yamada KM, Thiery JP. Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol Biol Cell 1994;5:851-62
41. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007;12:559-71
42. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-28
43. Alonso SR, Tracey L, Ortiz P, Perez-Gomez B, Palacios J, Pollan M, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 2007;67:3450-60
44. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 2000;148:779-90
45. Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, et al. Ncadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 2004;10:4125-33
46. Moalli F, Jaillon S, Inforzato A, Sironi M, Bottazzi B, Mantovani A, et al. Pathogen recognition by the long pentraxin PTX3. J Biomed Biotechnol 2011;2011:830421
47. Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels incancer progression. Oncogene 2012;31:4499-508
48. Cao R, Ji H, Feng N, Zhang Y, Yang X, Andersson P, et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci U S A 2012;109:15894-9
49. Greulich H, Pollock PM. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 2011;17:283-92
50. Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res 2009;7:41-54